Complejo Hospitalario QuirónSalud
- Address
- lock Available on a paid plan
Complejo Hospitalario QuirónSalud - Hematologic Malignancies Research
Complejo Hospitalario QuirónSalud serves as a prominent research institution specializing in advanced treatments for rare hematologic disorders. The center demonstrates particular expertise in managing complex myeloproliferative neoplasms, providing patients with access to cutting-edge therapeutic interventions through participation in extended access programs and long-term safety monitoring studies.
- Primary Myelofibrosis (PMF) treatment and management
- Post-Polycythemia Vera Myelofibrosis care
- Post-Essential Thrombocythemia Myelofibrosis research
The institution is committed to ensuring continuity of care for patients with myelofibrosis who demonstrate positive treatment responses, offering extended access to innovative therapies such as momelotinib. Through comprehensive long-term safety assessments, the center contributes valuable data to the understanding of sustained treatment outcomes in patients with myeloproliferative neoplasms, bridging the gap between clinical trial participation and ongoing therapeutic benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Complejo Hospitalario QuirónSalud
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Extended Access Study of Momelotinib Dihydrochloride Monohydrate in Patients with Primary Myelofibrosis or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | Glaxosmithkline Research & Development Limited | Phase II | Not Recruiting | Jul 2018 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Momelotinib Dihydrochloride Monohydrate | 1 | Unknown | 2018-07-27 | 2018-07-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.